

VZCZCXRO3770

PP RUEHHM RUEHLN RUEHMA RUEHPB

DE RUEHKO #6098 2920800

ZNR UUUUU ZZH

P 190800Z OCT 06

FM AMEMBASSY TOKYO

TO RUEHC/SECSTATE WASHDC PRIORITY 7597

INFO RUEHZN/ENVIRONMENT SCIENCE AND TECHNOLOGY COLLECTIVE

RUEHFK/AMCONSUL FUKUOKA 8516

RUEHNAG/AMCONSUL NAGOYA 8199

RUEHNH/AMCONSUL NAHA 1052

RUEHOK/AMCONSUL OSAKA KOBE 1895

RUEHKSO/AMCONSUL SAPPORO 9585

RUEHRC/USDA FAS WASHDC 8354

RUEAUSA/DEPT OF HHS WASHINGTON DC

RUEAIIA/CIA WASHDC

UNCLAS TOKYO 006098

SIPDIS

DEPT FOR AIAG AMBASSADOR LANGE

DEPT FOR OES/IHA SINGER AND FENDRICK

DEPT FOR EAP/J

USDA PASS TO APHIS

HHS PASS TO CDC

HHS FOR OGHA STEIGER, BHAT AND ELVANDER

DEPT PASS TO AID/GH/HIDN DENNIS CARROLL

SIPDIS

E.O. 12958: N/A

TAGS: TBIO KFLU KSTH ECON PREL SOCI JA

SUBJECT: AVIAN INFLUENZA: JAPAN WEEKLY REPORT OCTOBER 19

REF: A. 05 STATE 153802

IB. TOKYO 5970 AND PREVIOUS

11. There were no significant avian influenza (AI) developments in Japan during the period October 13 to October 19. No human or animal outbreaks of H5N1 AI were reported in Japan during the above period.

-- Japanese Developers Confirm the Effectiveness of a New AI Vaccine for Humans --

11. On October 17, four Japanese vaccine developers, including the Kitasato Research Institute, announced that they have confirmed the effectiveness of a new vaccine for human-to-human transmitted pandemic influenza. The vaccine was developed using an H5N1 AI virus taken from a human case of H5N1 infection in Vietnam, and has been in development, in cooperation with the National Institute of Infectious Diseases, since 2004. In July of this year, a phase I clinical trial of 360 healthy adult males confirmed both the vaccine's effectiveness in increasing levels of antibodies and its safety to humans. Large-scale phase II and III clinical trials began in September. The vaccine's developers plan to request approval from the Ministry of Health, Labor and Welfare to produce and sell the vaccine in 2007.

SCHIEFFER